TrialBlood2012

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

David S Siegel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.